PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
0.38%
Some net income increase while CRVO is negative at -42.83%. John Neff would see a short-term edge over the struggling competitor.
3.11%
Some D&A expansion while CRVO is negative at -0.39%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
-10.59%
Negative yoy deferred tax while CRVO stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
-5.75%
Negative yoy SBC while CRVO is 15.43%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
224.19%
Well above CRVO's 126.64% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
351.62%
AP growth well above CRVO's 112.20%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-1034.42%
Both reduce yoy usage, with CRVO at -71.07%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-5.75%
Negative yoy while CRVO is 232.10%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
10.47%
Operating cash flow growth below 50% of CRVO's 34.78%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
90.96%
CapEx growth well above CRVO's 100.00%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
90.96%
Investing outflow well above CRVO's 100.00%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
-1.15%
We cut debt repayment yoy while CRVO is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-84.36%
Negative yoy issuance while CRVO is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.